Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

39.76 -1.45 (-3.52%)
Streaming Delayed Price Updated: 1:52 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential ↗
Via Chartmill
News headline image
Veracyte Q2 Earnings Call Highlights ↗
Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD... 
Via MarketBeat
Topics Earnings
Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile ↗
Via Chartmill
News headline image
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. ↗
This genomic diagnostics company saw a notable insider sale, as shares have surged over 70% in the past year. 
Via The Motley Fool
Topics Regulatory Compliance
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT) ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price ↗
Via Chartmill
News headline image
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally ↗
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Veracyte Stock Is Skyrocketing Higher This Week ↗
Veracyte's first-quarter earnings were excellent, and the company's future looks bright. 
Via The Motley Fool
News headline image
Veracyte (VCYT) Q1 2026 Earnings Transcript ↗
Veracyte (VCYT) Q1 2026 Earnings Transcript 
Via The Motley Fool
Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗
Via Chartmill
Topics Earnings
Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗
Veracyte (VCYT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
Veracyte (VCYT) exemplifies GARP investing with strong cancer diagnostic growth, reasonable valuation vs. biotech peers, and a debt-free financial foundation. 
Via Chartmill
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
Veracyte (VCYT) offers affordable growth with strong earnings, a solid balance sheet, and reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗
Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗
Veracyte (VCYT) offers affordable growth with strong revenue & earnings expansion, a solid debt-free balance sheet, and reasonable valuation for the biotech sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.